Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.
Davis
Mark E
ME
Chemical Engineering, California Institute of Technology, Pasadena, California 91125, USA. mdavis@cheme.caltech.edu
Zuckerman
Jonathan E
JE
Choi
Chung Hang J
CH
Seligson
David
D
Tolcher
Anthony
A
Alabi
Christopher A
CA
Yen
Yun
Y
Heidel
Jeremy D
JD
Ribas
Antoni
A
D001706:Biopsy; D017321:Clinical Trials, Phase I as Topic; D004337:Drug Carriers / Q000008:administration & dosage / Q000493:pharmacokinetics; D016503:Drug Delivery Systems; D055785:Gene Knockdown Techniques / Q000379:methods*; D006801:Humans; D007275:Injections, Intravenous; D008545:Melanoma / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics; D053758:Nanoparticles / Q000008:administration & dosage / Q000032:analysis; D034622:RNA Interference / Q000187:drug effects*; D012333:RNA, Messenger / Q000032:analysis / Q000235:genetics / Q000378:metabolism; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000235:genetics / Q000494:pharmacology* / Q000627:therapeutic use; D011990:Receptors, Transferrin / Q000378:metabolism; D012262:Ribonucleoside Diphosphate Reductase / Q000096:biosynthesis / Q000235:genetics
D004337:Drug Carriers; D012333:RNA, Messenger; D034741:RNA, Small Interfering; D011990:Receptors, Transferrin; C093713:ribonucleotide reductase M2; D012262:Ribonucleoside Diphosphate Reductase